Summary of all Late-Breaking Trials at #ACC2026 – take home points
@ACCinTouch @ACCmediacenter @JACCJournals
1. HI-PEITHO: Ultrasound-facilitated catheter-directed thrombolysis led to a lower risk of PE-related death, cardiopulmonary decompensation or collapse, or recurrence of PE. vs anticoagulation alone in intermediate-high risk PE.
2. CHAMPION-AF: Left atrial appendage closure with the WATCHMAN FLX device had comparable 3-year risk of CV death/stroke/systemic embolism but reduced clinically-relevant non-procedural bleeding vs. DOACs in AFib.
Apr 9, 2024 • 15 tweets • 2 min read
Takeaways from #ACC2024. Late breaking trials - take home points @ACCinTouch
1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart transplantation, HF hospitalizations, outpatient worsening HF events.
2. EMPACT-MI Trial: Among patients at increased risk for HF after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for HF or death from any cause than placebo.
